To our valued partners and colleagues,
Like so many of you, we experienced both remarkable achievements and unimaginable sadness in 2020. But as I reflect, I’m proud of the resilience our industry has exhibited and the progress we’ve made toward our collective goal of making the world a better, healthier, and more inclusive place. 2020 was also a year for soul searching, and we sought to evolve how we support our partners, each other, and the industry we serve.
Thanks to you and many others, I’m thrilled to outline how we will help our partners Go Beyond and Deliver More in 2021.
Speed and agility.
Faster startup, faster results, faster to adapt to change—that’s our promise to you. Leveraging new processes and technology, we’ve rolled out an improved startup approach that enables us to launch programs faster than ever before while rapidly responding to the dynamics that can impact enrollment.
New, innovative solutions.
2021 brings new capabilities like live secondary screening to improve referral quality, a new partnership with ACRP for clinical trial insights, and portfolio-wide recruitment solutions that deliver scale and efficiency. We launched new technology solutions that improve campaign ROI and enhance the patient and site experience.
Unmatched visibility.
Our enhanced ContinuVue® technology platform gives you unprecedented enrollment visibility with up-to-the-minute reporting on site performance and outreach campaign results, providing insight into what’s happening (and why) at every step of the patient journey—from any vendor or tactic—all rolled up neatly into one single source of easy-to-navigate truth.
While we’ve evolved and grown over the last 28 years, one thing has always remained the same: we measure our success by your success. Thank you for trusting Continuum to be the best possible partner to meet your trial’s recruitment and retention goals. I look forward to the opportunity to continue to help solve your enrollment challenges together.
With gratitude,
Neil Weisman
President, Continuum Clinical
